免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Identification of the Epigenetic Response to Trauma (TrauMeth)

Identification of the Epigenetic Response to Trauma (TrauMeth)

Study Description
Brief Summary:
The objective of this study is to investigate potential early alterations in the DNA methylation profile after severe trauma and to investigate if the early marks persist.

Condition or disease Intervention/treatment
Trauma Injuries Diagnostic Test: Blood samples for DNA methylation analysis

Detailed Description:

Background: Severe trauma is an extreme physical exposure, which may have significant consequences for the patient. In addition to anatomical injury and hemodynamic compromise, severe trauma causes an immense and rapid systemic immune reaction. At the genomic level, trauma has been found to significantly increase gene expression in circulating leukocytes, and preliminary data is also emerging that trauma may even cause epigenetic (DNA methylation) alterations.

Epigenetics, including DNA methylation, have been suggested as a mediator of genetic risk and to play a significant role in subsequent non-traumatic disease. Within the field of trauma DNA methylation has only been sparsely studied, but a few studies of traumatized animals have suggested that DNA methylation alterations may occur in relation to trauma. Even though DNA methylation is highly dynamic, some marks have been found to be stable over time, and thus may have long-term consequences.

An increasing understanding of the role of epigenetics in disease development and response may pave the way for new treatment targets and modalities for multiple diseases including trauma.

Research question: Does trauma induce immediate (<4 hours) and persistent (30 days post-trauma) changes in the epigenome of peripheral blood cells, and do epigenetic changes correlate with patient recovery?

Objectives: To identify potential early alterations in the DNA methylation profile after severe trauma AND to investigate if the early marks persist.

Study design: A prospective, observational, cohort study of trauma patients admitted to RH's trauma center. The trauma cohort will be compared to a cohort of patients admitted for elective orthopedic surgery in terms of DNA methylation profile in blood cells pre-trauma/surgery, immediately post-trauma/surgery, and 30-45 days post-trauma/surgery.

DNA methylation profiles will be assessed by array technique using Illumina's MethylationEPIC Bead-Chip.

Primary outcome: Immediate (<4 hours) post-trauma DNA methylation profile in blood cells.

Secondary outcomes: Pre-trauma/surgery DNA methylation profile, change in DNA methylation from pre-trauma/surgery to immediately and 30 days post-trauma/surgery, occurrence of organ dysfunction, sepsis, septic shock, 30-day mortality, ICU admission > 24 hours, ICU length of stay (LOS), hospital LOS.

Study Design
Layout table for study information
Study Type : Observational
Actual Enrollment : 365 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Identification of the Epigenetic Response to Trauma - a Prospective, Observational Study
Actual Study Start Date : June 3, 2019
Actual Primary Completion Date : April 15, 2021
Estimated Study Completion Date : December 31, 2021
Arms and Interventions
Group/Cohort Intervention/treatment
Trauma patients
All trauma patients admitted to Rigshospitalet's trauma center will have a blood sample taken during the initial treatment and 30 days after the trauma.
Diagnostic Test: Blood samples for DNA methylation analysis
DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).

Patients admitted for elective orthopedic surgery
The patients will have a blood sample taken before and after surgery and again 30 days after the surgery.
Diagnostic Test: Blood samples for DNA methylation analysis
DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).

Outcome Measures
Primary Outcome Measures :
  1. Immediate DNA methylation profile [ Time Frame: Day of trauma/surgery ]
    Immediate (< 4 hours) post-trauma DNA methylation profile in blood cells compared to the pre-surgery (baseline) and immediate post-surgery (< 4 hours) DNA methylation profile in blood cells.


Secondary Outcome Measures :
  1. Pre-trauma/-surgery DNA methylation profile [ Time Frame: Pre-trauma/surgery ]
    Pre-trauma (if possible to obtain from an existing biobank) DNA methylation profile in blood cells compared to pre-surgery.

  2. Stability of DNA methylation profile [ Time Frame: 30-45 days after trauma/surgery ]
    Persistence of the DNA methylation profile in blood cells 30-45 days after the trauma compared to surgical patients.

  3. Change in DNA methylation profile; pre-trauma/-surgery to post-trauma/-surgery [ Time Frame: Day of trauma/surgery ]
    Change in DNA methylation profile in blood cells from pre-trauma (if possible to obtain) to immediately post-trauma compared to surgical patients.

  4. Change in DNA methylation profile; immediately post-trauma/-surgery to one month post-trauma/-surgery [ Time Frame: 0 to 30-45 days after trauma/surgery ]
    Change in DNA methylation profile in blood cells from immediately post-trauma to 30-45 days post-trauma compared to surgical patients.

  5. DNA methylation changes in relation to injury severity [ Time Frame: Day 0-45 after trauma/surgery ]
    Association of DNA methylation changes with injury severity. This will be done by comparing the DNA methylation profiles among patient with an injury severity score (ISS) < 15 and patients with an ISS > 15.

  6. Organ dysfunction [ Time Frame: Day 30 after trauma/surgery ]
    Occurrence of organ dysfunction (increase of ≥ 2 in SOFA-score)

  7. Sepsis/septic shock [ Time Frame: Day 30 after trauma/surgery ]
    Occurrence of sepsis or septic shock


Biospecimen Retention:   Samples With DNA
Blood samples are obtained from patients to investigate DNA methylation profiles

Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The study population consists of all trauma patients admitted to RH's trauma center generating a trauma team activation.

The control group will consist of patients admitted to RH's orthopedic department for elective surgery.

Criteria

Inclusion Criteria:

  • Age 18-65 years.
  • Trauma patients: Admitted to Rigshospitalet's trauma center generating a trauma team activation.
  • Surgical controls: Admitted for elective surgery (non-traumatic cause) at the orthopedics department AND

    • Only one surgical procedure planned from study day 0 to study day 45.
    • Expected procedure length of at least 60 minutes.

Exclusion Criteria:

  • Not able to obtain informed consent and not possible to obtain consent from a next-of-kin.
  • Trauma patients:

    • Secondary transfers.
    • Pre-hospital blood transfusion OR blood transfusion in the trauma center before the first blood sample is obtained.
    • First blood sample taken later than 4 hours after the trauma.
    • Patients in cardiac arrest before/after hospital admission.
    • Additional traumatic exposure requiring hospital admission between the collection of the primary blood sample and the follow-up blood sample (will cause exclusion from follow-up blood sample).
    • Surgery not related to the trauma between the collection of the primary blood sample and the follow-up blood sample (will cause exclusion from follow-up blood sample).
  • Surgical controls:

    • Surgical procedures due to cancer or fractures.
    • Traumatic exposure requiring hospital admission between the collection of the primary blood sample and the follow-up blood sample (will cause exclusion from follow-up blood sample).
    • Additional, unplanned surgery between the collection of the primary blood sample and the follow-up blood sample (will cause exclusion from follow-up blood sample).
    • First post-operative blood sample taken later than 4 hours after surgical end time.
Contacts and Locations

Locations
Layout table for location information
Denmark
Rigshospitalet
Copenhagen, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Investigators
Layout table for investigator information
Study Director: Jacob Steinmetz, MD, Ph.D. Rigshospitalet, Denmark
Tracking Information
First Submitted Date May 29, 2019
First Posted Date June 4, 2019
Last Update Posted Date May 7, 2021
Actual Study Start Date June 3, 2019
Actual Primary Completion Date April 15, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: June 3, 2019)
Immediate DNA methylation profile [ Time Frame: Day of trauma/surgery ]
Immediate (< 4 hours) post-trauma DNA methylation profile in blood cells compared to the pre-surgery (baseline) and immediate post-surgery (< 4 hours) DNA methylation profile in blood cells.
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: June 3, 2019)
  • Pre-trauma/-surgery DNA methylation profile [ Time Frame: Pre-trauma/surgery ]
    Pre-trauma (if possible to obtain from an existing biobank) DNA methylation profile in blood cells compared to pre-surgery.
  • Stability of DNA methylation profile [ Time Frame: 30-45 days after trauma/surgery ]
    Persistence of the DNA methylation profile in blood cells 30-45 days after the trauma compared to surgical patients.
  • Change in DNA methylation profile; pre-trauma/-surgery to post-trauma/-surgery [ Time Frame: Day of trauma/surgery ]
    Change in DNA methylation profile in blood cells from pre-trauma (if possible to obtain) to immediately post-trauma compared to surgical patients.
  • Change in DNA methylation profile; immediately post-trauma/-surgery to one month post-trauma/-surgery [ Time Frame: 0 to 30-45 days after trauma/surgery ]
    Change in DNA methylation profile in blood cells from immediately post-trauma to 30-45 days post-trauma compared to surgical patients.
  • DNA methylation changes in relation to injury severity [ Time Frame: Day 0-45 after trauma/surgery ]
    Association of DNA methylation changes with injury severity. This will be done by comparing the DNA methylation profiles among patient with an injury severity score (ISS) < 15 and patients with an ISS > 15.
  • Organ dysfunction [ Time Frame: Day 30 after trauma/surgery ]
    Occurrence of organ dysfunction (increase of ≥ 2 in SOFA-score)
  • Sepsis/septic shock [ Time Frame: Day 30 after trauma/surgery ]
    Occurrence of sepsis or septic shock
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Identification of the Epigenetic Response to Trauma
Official Title Identification of the Epigenetic Response to Trauma - a Prospective, Observational Study
Brief Summary The objective of this study is to investigate potential early alterations in the DNA methylation profile after severe trauma and to investigate if the early marks persist.
Detailed Description

Background: Severe trauma is an extreme physical exposure, which may have significant consequences for the patient. In addition to anatomical injury and hemodynamic compromise, severe trauma causes an immense and rapid systemic immune reaction. At the genomic level, trauma has been found to significantly increase gene expression in circulating leukocytes, and preliminary data is also emerging that trauma may even cause epigenetic (DNA methylation) alterations.

Epigenetics, including DNA methylation, have been suggested as a mediator of genetic risk and to play a significant role in subsequent non-traumatic disease. Within the field of trauma DNA methylation has only been sparsely studied, but a few studies of traumatized animals have suggested that DNA methylation alterations may occur in relation to trauma. Even though DNA methylation is highly dynamic, some marks have been found to be stable over time, and thus may have long-term consequences.

An increasing understanding of the role of epigenetics in disease development and response may pave the way for new treatment targets and modalities for multiple diseases including trauma.

Research question: Does trauma induce immediate (<4 hours) and persistent (30 days post-trauma) changes in the epigenome of peripheral blood cells, and do epigenetic changes correlate with patient recovery?

Objectives: To identify potential early alterations in the DNA methylation profile after severe trauma AND to investigate if the early marks persist.

Study design: A prospective, observational, cohort study of trauma patients admitted to RH's trauma center. The trauma cohort will be compared to a cohort of patients admitted for elective orthopedic surgery in terms of DNA methylation profile in blood cells pre-trauma/surgery, immediately post-trauma/surgery, and 30-45 days post-trauma/surgery.

DNA methylation profiles will be assessed by array technique using Illumina's MethylationEPIC Bead-Chip.

Primary outcome: Immediate (<4 hours) post-trauma DNA methylation profile in blood cells.

Secondary outcomes: Pre-trauma/surgery DNA methylation profile, change in DNA methylation from pre-trauma/surgery to immediately and 30 days post-trauma/surgery, occurrence of organ dysfunction, sepsis, septic shock, 30-day mortality, ICU admission > 24 hours, ICU length of stay (LOS), hospital LOS.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
Blood samples are obtained from patients to investigate DNA methylation profiles
Sampling Method Probability Sample
Study Population

The study population consists of all trauma patients admitted to RH's trauma center generating a trauma team activation.

The control group will consist of patients admitted to RH's orthopedic department for elective surgery.

Condition
  • Trauma
  • Injuries
Intervention Diagnostic Test: Blood samples for DNA methylation analysis
DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).
Study Groups/Cohorts
  • Trauma patients
    All trauma patients admitted to Rigshospitalet's trauma center will have a blood sample taken during the initial treatment and 30 days after the trauma.
    Intervention: Diagnostic Test: Blood samples for DNA methylation analysis
  • Patients admitted for elective orthopedic surgery
    The patients will have a blood sample taken before and after surgery and again 30 days after the surgery.
    Intervention: Diagnostic Test: Blood samples for DNA methylation analysis
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Active, not recruiting
Actual Enrollment
 (submitted: May 6, 2021)
365
Original Estimated Enrollment
 (submitted: June 3, 2019)
360
Estimated Study Completion Date December 31, 2021
Actual Primary Completion Date April 15, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Age 18-65 years.
  • Trauma patients: Admitted to Rigshospitalet's trauma center generating a trauma team activation.
  • Surgical controls: Admitted for elective surgery (non-traumatic cause) at the orthopedics department AND

    • Only one surgical procedure planned from study day 0 to study day 45.
    • Expected procedure length of at least 60 minutes.

Exclusion Criteria:

  • Not able to obtain informed consent and not possible to obtain consent from a next-of-kin.
  • Trauma patients:

    • Secondary transfers.
    • Pre-hospital blood transfusion OR blood transfusion in the trauma center before the first blood sample is obtained.
    • First blood sample taken later than 4 hours after the trauma.
    • Patients in cardiac arrest before/after hospital admission.
    • Additional traumatic exposure requiring hospital admission between the collection of the primary blood sample and the follow-up blood sample (will cause exclusion from follow-up blood sample).
    • Surgery not related to the trauma between the collection of the primary blood sample and the follow-up blood sample (will cause exclusion from follow-up blood sample).
  • Surgical controls:

    • Surgical procedures due to cancer or fractures.
    • Traumatic exposure requiring hospital admission between the collection of the primary blood sample and the follow-up blood sample (will cause exclusion from follow-up blood sample).
    • Additional, unplanned surgery between the collection of the primary blood sample and the follow-up blood sample (will cause exclusion from follow-up blood sample).
    • First post-operative blood sample taken later than 4 hours after surgical end time.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Denmark
Removed Location Countries  
 
Administrative Information
NCT Number NCT03974048
Other Study ID Numbers VD-2019-161
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Trine Grodum Eskesen, Rigshospitalet, Denmark
Study Sponsor Rigshospitalet, Denmark
Collaborators Not Provided
Investigators
Study Director: Jacob Steinmetz, MD, Ph.D. Rigshospitalet, Denmark
PRS Account Rigshospitalet, Denmark
Verification Date May 2021